Clinical Trials
-
Publication Venue For
- User-centered design principles in the development of clinical research tools.. 17:703-711. 2020
- Organizational- and employee-level recruitment into a worksite-based weight loss study.. 9:215-225. 2012
- Independent but coordinated trials: insights from the practice-based Opportunities for Weight Reduction Trials Collaborative Research Group.. 7:322-332. 2010
- Caregiver-assisted coping skills training for patients with COPD: background, design, and methodological issues for the INSPIRE-II study.. 6:172-184. 2009
- Outcomes following vaginal prolapse repair and mid urethral sling (OPUS) trial--design and methods.. 6:162-171. 2009
- What can we learn from a decade of database audits? The Duke Clinical Research Institute experience, 1997--2006.. 6:141-150. 2009
- A centralized informatics infrastructure for the National Institute on Drug Abuse Clinical Trials Network.. 6:67-75. 2009
- Authors' response. 5:223-224. 2008
- Erratum: Meta-analysis of rare events: An update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone (Clinical Trials (2008) vol. 5(2) (116-20) 10.1177/1740774508090212). 5:559. 2008
- Response to letter of Meinert et al. 5:558. 2008
- Comment regarding benefit in phase 1 oncology trials.. 5:626. 2008
- Design considerations and rationale of a multi-center trial to sustain weight loss: the Weight Loss Maintenance Trial.. 5:546-556. 2008
- Designing phase II studies in cancer with time-to-event endpoints.. 5:209-221. 2008
- Do we need to adjudicate major clinical events?. 5:56-60. 2008
- Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.. 5:116-120. 2008
- Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer.. 5:262-272. 2008
- Sensible approaches for reducing clinical trial costs.. 5:75-84. 2008
- Sensible guidelines for the conduct of large randomized trials.. 5:38-39. 2008
- The impact of privacy and confidentiality laws on the conduct of clinical trials.. 5:70-74. 2008
- Using item banks to construct measures of patient reported outcomes in clinical trials: investigator perceptions.. 5:575-586. 2008
- Varieties of uncertainty and the validity of informed consent.. 5:624-625. 2008
- A study design to assess the safety and efficacy of on-pump versus off-pump coronary bypass grafting: the ROOBY trial.. 4:81-91. 2007
- Integrating smoking cessation into mental health care for post-traumatic stress disorder.. 4:178-189. 2007
- Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.. 4:218-234. 2007
- Non-surgical management of stress urinary incontinence: ambulatory treatments for leakage associated with stress (ATLAS) trial.. 4:92-101. 2007
- Perspectives of clinical research coordinators on disclosing financial conflicts of interest to potential research participants.. 4:272-278. 2007
- Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study--rationale, design, and methodological issues.. 4:548-559. 2007
- Who refuses enrollment in cardiac clinical trials?. 4:258-263. 2007
- Erratum: Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial (Clinical Trials 2 (400-412)). 3:160. 2006
- Clinical trials bureaucracy: unintended consequences of well-intentioned policy.. 3:496-502. 2006
- Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.. 3:335-348. 2006
- Cost-effectiveness as an outcome in randomized clinical trials.. 3:543-551. 2006
- The Society for Clinical Trials opposes US legislation to permit marketing of unproven medical therapies for seriously ill patients.. 3:154-157. 2006
- Equipoise in the Enhanced Supression of the Platelet IIb/IIIa Receptor with Integrilin Trial (ESPRIT): A critical appraisal. Comment. 2:242-243. 2005
- A general formulation for a one-sided group sequential design.. 2:519-528. 2005
- Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial.. 2:400-412. 2005
- Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.. 2:413-422. 2005
- The Society for Clinical Trials supports United States legislation mandating trials registration.. 2:193. 2005
- Issues in regulatory guidelines for data monitoring committees.. 1:162-169. 2004
- Liability issues for data monitoring committee members.. 1:525-531. 2004
- The Society for Clinical Trials supports United States legislation mandating trials registration. Position paper.. 1:417-420. 2004
- Panel discussion of case study 3 2005